ClinicalTrials.gg
RecruitingNCT06915142Updated Jan 26, 2026

A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour

A Phase 2 interventional study of HRS-7058 + SHR-1316 and HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy in Advanced Malignant Tumour, sponsored by Shandong Suncadia Medicine Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is a multicentre, open phase II clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in combination with antitumor drugs in subjects with advanced malignant tumour. To evaluate the safety, tolerability and efficacy of HRS-7058 in combination with antitumor drugs.

02

Conditions studied

  • Advanced Malignant Tumour
03

In context

Lead sponsor

Shandong Suncadia Medicine Co., Ltd. is the lead sponsor of 87 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subjects gave to the study before participating in, and voluntarily signed informed consent;
  2. 18 to 75 years old (including both ends), gender is not limited;
  3. Subjects with unresectable locally advanced or solid tumour confirmed by histopathology;
  4. Having at least one evaluable or according to the solid tumour response Evaluation Criteria ( 1.1);
  5. Performance Status of 0 or 1;
  6. The expected survival time is more than 12 weeks;
  7. Be able to ingest drugs and be able to comply with trial and follow-up procedures;
  8. Adequate bone marrow and organ function;
  9. Female subjects of must undergo a serum pregnancy test within 7 days before the first administration of the study drug, and the result must be negative; and they must not be lactating. Female subjects of childbearing potential and male subjects whose partners are females of childbearing potential must agree to comply with requirements from the time of signing the informed consent form until 5 months after the last administration of the study drug (for male subjects) or 8 months after the last administration of the study drug (for female subjects).

Exclusion criteria

Exclusion Criteria:

  1. Accompanied by untreated or active central nervous system (CNS) tumour ;
  2. Antitumor therapy within 28 days prior to initial use of the drug;
  3. The adverse reactions of previous anti-tumour therapy have not recovered to ≤ grade 1;
  4. With known or suspected interstitial pneumonia;
  5. With severe cardiovascular and cerebrovascular disease
  6. Had other within five years prior to first use of the investigational drug;
  7. Severe infection within 28 days prior to first use of the investigational drug;
  8. History of immune deficiency;
  9. nausea, vomiting, or other gastrointestinal disorders that affect the use of oral medications;
  10. The presence of uncontrolled pleural, abdominal or pericardial effusion;
  11. Had undergone major organ surgery within 28 days prior to the first use of the study drug;
  12. Women during pregnancy or lactation;
  13. Known allergies and to the investigational drug or any of its components;
  14. According to the judgment of the investigator, there are any other circumstances that may increase the risks of participating in the study, interfere with the study results, or make the subjects unsuitable for participating in this study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    HRS-7058 + SHR-1316

    Drug: HRS-7058 + SHR-1316

  • Experimental
    HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy

    Drug: HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy

  • Experimental
    HRS-7058 + Cetuximab

    Drug: HRS-7058 + Cetuximab

  • Experimental
    HRS-7058 + SHR-1826

    Drug: HRS-7058 + SHR-1826

  • Experimental
    HRS-7058 + SHR-1826 + SHR-1316

    Drug: HRS-7058 + SHR-1826 + SHR-1316

  • Experimental
    HRS-7058 + SHR-A1202

    Drug: HRS-7058 + SHR-A1202

  • Experimental
    HRS-7058 + BP102

    Drug: HRS-7058 + BP102

  • Experimental
    HRS-7058 + SHR-9839

    Drug: HRS-7058 + SHR-9839

  • Experimental
    HRS-7058 +SHR-A2102 +SHR-1316

    Drug: HRS-7058 +SHR-A2102 +SHR-1316

  • Experimental
    HRS-7058 +SHR-9839(sc)+SHR-1316

    Drug: HRS-7058 +SHR-9839(sc)+SHR-1316

  • Experimental
    HRS-7058 +SHR-1316 +BP102

    Drug: HRS-7058 +SHR-1316 +BP102

  • Experimental
    HRS-7058 +SHR-A2102 +BP102

    Drug: HRS-7058 +SHR-A2102 +BP102

  • Experimental
    HRS-7058 +SHR-A2102 +SHR-1316 +BP102

    Drug: HRS-7058 +SHR-A2102 +SHR-1316 +BP102

Interventions

  • DrugHRS-7058 + SHR-1316

    Drug pages: HRS-7058 · Adebrelimab

    HRS-7058 + SHR-1316

  • DrugHRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy

    HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy

  • DrugHRS-7058 + Cetuximab

    Drug pages: HRS-7058 · Cetuximab

    HRS-7058 + Cetuximab

  • DrugHRS-7058 + SHR-1826

    HRS-7058 + SHR-1826

  • DrugHRS-7058 + SHR-1826 + SHR-1316

    Drug pages: HRS-7058 · SHR-1826 · Adebrelimab

    HRS-7058 + SHR-1826 + SHR-1316

  • DrugHRS-7058 + SHR-A1202

    HRS-7058 + SHR-A1202

  • DrugHRS-7058 + BP102

    Drug page: BP102

    HRS-7058 + BP102

  • DrugHRS-7058 + SHR-9839

    HRS-7058 + SHR-9839

  • DrugHRS-7058 +SHR-A2102 +SHR-1316

    Drug pages: HRS-7058 · Notiretatug rezetecan · Adebrelimab

    HRS-7058 +SHR-A2102 +SHR-1316

  • DrugHRS-7058 +SHR-9839(sc)+SHR-1316

    Drug pages: HRS-7058 · SHR-9839 · Adebrelimab

    HRS-7058 +SHR-9839(sc)+SHR-1316

  • DrugHRS-7058 +SHR-1316 +BP102

    Drug page: BP102

    HRS-7058 +SHR-1316 +BP102

  • DrugHRS-7058 +SHR-A2102 +BP102

    Drug page: BP102

    HRS-7058 +SHR-A2102 +BP102

  • DrugHRS-7058 +SHR-A2102 +SHR-1316 +BP102

    Drug page: BP102

    HRS-7058 +SHR-A2102 +SHR-1316 +BP102

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT) (Dose Escalation and Dose Expansion)

    Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months

  2. Safety endpoints: adverse events (AE) (Dose Escalation and Dose Expansion)

    Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months]

  3. Phase II recommended dose (RP2D)(Dose Escalation and Dose Expansion)

    Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months]

  4. Efficacy endpoints: Objective response rate (ORR) assessed based on RECIST v1.1 criterion (Efficacy Expansion)

    Time frame: From the beginning of first patient in (FPI) to the end of study up to approximately 32 months

Secondary outcomes

  1. Efficacy endpoints: Objective response rate (ORR) assessed based on RECIST v1.1 criterion (Dose Escalation and Dose Expansion)

    Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months

  2. Efficacy endpoints: disease control rate (DCR) assessed based on RECIST v1.1 criterion (Dose Escalation and Dose Expansion)

    Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months

  3. Efficacy endpoints: duration of response (DoR) assessed based on RECIST v1.1 criterion (Dose Escalation and Dose Expansion)

    Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months

  4. Efficacy endpoints: progression-free survival (PFS) assessed based on RECIST v1.1 criterion (Dose Escalation and Dose Expansion)

    Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months

  5. Efficacy endpoints: overall survival (OS)(Dose Escalation and Dose Expansion)

    Time frame: From the beginning of first patient in (FPI) to the end of dose expansion phase up to approximately 10 months

  6. Efficacy endpoints: disease control rate (DCR) assessed based on RECIST v1.1 criterion (Efficacy Expansion)

    Time frame: From the beginning of first patient in (FPI) to the end of study up to approximately 32 months

  7. Efficacy endpoints: duration of response (DoR) assessed based on RECIST v1.1 criterion (Efficacy Expansion)

    Time frame: From the beginning of first patient in (FPI) to the end of study up to approximately 32 months

  8. Efficacy endpoints: progression-free survival (PFS) assessed based on RECIST v1.1 criterion (Efficacy Expansion)

    Time frame: From the beginning of first patient in (FPI) to the end of study up to approximately 32 months

  9. Efficacy endpoints: overall survival (OS) (Efficacy Expansion)

    Time frame: From the beginning of first patient in (FPI) to the end of study up to approximately 32 months

  10. Safety endpoints: adverse events (AE)(Efficacy Expansion)

    Time frame: From the beginning of first patient in (FPI) to the end of study up to approximately 32 months

07

Study locations

2 of 2 sites recruiting
  • Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
    Beijing, Beijing Municipality 100021, China
    Recruiting
    • Yan Wang · Principal investigator
  • Tianjin Cancer Hospital
    Tianjin, Tianjin Municipality 300060, China
    Recruiting
    • Dingzhi Huang · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2025
First posted
Apr 8, 2025
StartActual
Apr 28, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Oct 2027
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06915142
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
Apr 28, 2025
Primary completion
Dec 2026 (estimated)
Completion
Oct 2027 (estimated)
Last update
Jan 26, 2026

Study contacts

Sida Zhu
Contact
sida.zhu.sz15@hengrui.com
+0518-81220121
Linan Wang
Contact
linan.wang@hengrui.com
+0518-81220121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HRS-7058 · Adebrelimab · Cetuximab · SHR-1826 · BP102 · Notiretatug rezetecan · SHR-9839

Start the discussion